Emerging role of nuclear phospholipase C-β1 in lung cancer
6 affiliations
- 1Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna
- 2Unit of Clinic Pathology, The Greater Romagna Area Hub Laboratory, Cesena
- 3Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna
- 4Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC)
- 5Pathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì
- 6Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy
Abstract
Non-small cell lung cancer (NSCLC) is a highly aggressive malignancy accounting for approximately 85% of all lung cancer cases. To better understand its pathology and prognosis, this study focused on the molecular profiling of tissues and clinical outcomes derived directly from lung cancer patients. Recently, the involvement of phospholipase enzymes in cancer has been highlighted, as they are involved in crucial cellular signaling pathways. The mRNA and protein expression levels of phospholipase C (PLC) isoforms were analyzed in biopsies from NSCLC patients. Utilizing Kaplan-Meier plotter database, the prognostic role of PLCs could be assessed. Researchers identified significant changes in mRNA and protein expression levels of various PLC isoforms in patient biopsies. Notably, PLCβ1 was found to be overexpressed in every tumor sample. In addition, the use of KM-Plotter hypothesized an association between elevated PLCβ1 levels and poorer survival outcomes, emphasizing the variations due to patient-specific factors, such as tumor stage and smoking history. Immunohistochemistry performed on patient-derived samples revealed a clear contrast in protein localization. In tumor tissues, PLCβ1 was predominantly found in the nucleus, whereas in adjacent healthy tissues, it remained almost exclusively in the cytoplasm. Nuclear localization is known to be linked to cell cycle modulation; therefore, it may represent a critical event in cancer development. The study highlighted critical alterations in PLC isoforms observed within the patient population. These findings demonstrate that PLCβ1 is significantly upregulated in malignant tissues and correlates with adverse clinical outcomes. Consequently, PLCβ1 may serve as a candidate biomarker, warranting further investigation into its potential role in the management and treatment of NSCLC patients.
Related
- Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
- EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies
- Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
- Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.
- Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches
BibTeX
@article{versari2026emerging,
title = {{Emerging role of nuclear phospholipase C-β1 in lung cancer}},
author = {Ilaria Versari and Sara Salucci and Anna Bartoletti Stella and Stefania Benini and Marco Gambarotti and Camilla Sbrighi and Paola Ulivi and Andrea Ambrosini Spaltro and Mirko Traversari and Franco Stella and Beatrice Aramini and Irene Faenza},
journal = {European Journal of Histochemistry : EJH},
year = {2026},
month = oct,
doi = {10.4081/ejh.2026.4774},
url = {https://doi.org/10.4081/ejh.2026.4774},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Emerging role of nuclear phospholipase C-β1 in lung cancer
AU - Ilaria Versari
AU - Sara Salucci
AU - Anna Bartoletti Stella
AU - Stefania Benini
AU - Marco Gambarotti
AU - Camilla Sbrighi
AU - Paola Ulivi
AU - Andrea Ambrosini Spaltro
AU - Mirko Traversari
AU - Franco Stella
AU - Beatrice Aramini
AU - Irene Faenza
PY - 2026
DA - 2026/10/29
JO - European Journal of Histochemistry : EJH
DO - 10.4081/ejh.2026.4774
UR - https://doi.org/10.4081/ejh.2026.4774
AB - Non-small cell lung cancer (NSCLC) is a highly aggressive malignancy accounting for approximately 85% of all lung cancer cases. To better understand its pathology and prognosis, this study focused on the molecular profiling of tissues and clinical outcomes derived directly from lung cancer patients. Recently, the involvement of phospholipase enzymes in cancer has been highlighted, as they are involved in crucial cellular signaling pathways. The mRNA and protein expression levels of phospholipase C (PLC) isoforms were analyzed in biopsies from NSCLC patients. Utilizing Kaplan-Meier plotter database, the prognostic role of PLCs could be assessed. Researchers identified significant changes in mRNA and protein expression levels of various PLC isoforms in patient biopsies. Notably, PLCβ1 was found to be overexpressed in every tumor sample. In addition, the use of KM-Plotter hypothesized an association between elevated PLCβ1 levels and poorer survival outcomes, emphasizing the variations due to patient-specific factors, such as tumor stage and smoking history. Immunohistochemistry performed on patient-derived samples revealed a clear contrast in protein localization. In tumor tissues, PLCβ1 was predominantly found in the nucleus, whereas in adjacent healthy tissues, it remained almost exclusively in the cytoplasm. Nuclear localization is known to be linked to cell cycle modulation; therefore, it may represent a critical event in cancer development. The study highlighted critical alterations in PLC isoforms observed within the patient population. These findings demonstrate that PLCβ1 is significantly upregulated in malignant tissues and correlates with adverse clinical outcomes. Consequently, PLCβ1 may serve as a candidate biomarker, warranting further investigation into its potential role in the management and treatment of NSCLC patients.
SN - 1121-760X
SN - 2038-8306
ER -